Clostilbegyt, tablets 50 mg 10 pcs.

Clostilbegyt is an anti-estrogenic drug of non-steroidal structure.

The mechanism of action is due to specific binding to estrogen receptors of the ovaries and pituitary gland.

In low estrogen content in the body it shows moderate estrogenic effect, in high content – anti-estrogenic effect.

In low doses it increases gonadotropin secretion (prolactin, FSH and LH), stimulates ovulation; in high doses it inhibits gonadotropin secretion.

He has no gestagenic and androgenic activity.

Indications

Anovulatory infertility (ovulation induction).
Amenorrhea (dysgonadotropic form).
Secondary amenorrhea.
Postcontraceptive amenorrhea.
Stein-Leventhal syndrome (polycystic ovary syndrome).
Oligomenorrhea.
Galactorrhea (against the background of a pituitary tumor).
Chiari-Frommel syndrome (prolonged postpartum amenorrhea-galactorrhea syndrome).
Androgen deficiency.
In men: oligospermia.

Pharmacological effect

Clostilbegit is an anti-estrogenic drug with a non-steroidal structure.

The mechanism of action is due to specific binding to estrogen receptors of the ovaries and pituitary gland.

When the content of estrogen in the body is low, it exhibits a moderate estrogenic effect, and when the content is high, it has an antiestrogenic effect.

In small doses, it enhances the secretion of gonadotropins (prolactin, FSH and LH), stimulates ovulation; in high doses inhibits the secretion of gonadotropins.

It does not have gestagenic or androgenic activity.

Special instructions

Before starting the drug, it is recommended to study liver function. Before starting treatment, a thorough gynecological examination should be performed. Treatment begins when the total content of gonadotropin in the urine is normal or below the lower limit of normal, the condition of the ovaries during palpation is normal, and the functions of the thyroid gland and adrenal glands are normal. If there is no ovulation, all other possible forms of infertility should be excluded or treated before starting to use the drug.

If ovarian enlargement or cystic changes occur while taking the drug, treatment should be discontinued until the size of the ovaries returns to normal. In the future, you can resume taking it, but at the same time reduce the dose of the drug or the duration of treatment.

During the treatment process, constant supervision by a gynecologist is necessary, ovarian functions should be monitored, vaginal examinations should be performed, and the “pupil” phenomenon should be observed. Often during the course of treatment it is difficult to determine the moment of ovulation, and insufficiency of the corpus luteum is also often observed. Therefore, after conception, prophylactic treatment with progesterone is recommended.

The drug is contraindicated in patients with galactose intolerance, lactase deficiency or glucose malabsorption, because each tablet contains 100 mg of lactose.

Since the drug can cause visual impairment, during treatment patients should be careful when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Clomiphene

Composition

1 tablet contains:

Active substance:

clomiphene citrate 50 mg;

Excipients:

gelatin,

magnesium stearate,

stearic acid,

talc,

potato starch,

lactose monohydrate.

Pregnancy

Contraindicated for use during pregnancy and breastfeeding.

Contraindications

Liver and/or renal failure.
Ovarian cyst (except for polycystic ovary syndrome).
Tumor or hypofunction of the pituitary gland.
Thyroid gland dysfunction.
Adrenal gland dysfunction.
Metrorrhagia of unknown etiology.
Long-term or recently developed visual impairment.
Neoplasms of the genital organs.
Endometriosis.
Insufficiency of ovarian function due to hyperprolactinemia.
Pregnancy.
Lactation (breastfeeding).
Galactose intolerance, lactase deficiency or glucose malabsorption.
Hypersensitivity to the components of the drug.

Side Effects

From the digestive system: nausea, vomiting; rarely – gastralgia, flatulence, diarrhea, acute abdominal syndrome, increased appetite.

From the side of the central nervous system: headache, dizziness, drowsiness; rarely – slowed mental and motor reactions, increased excitability, depression, insomnia.

From the senses: visual impairment (including impaired perception of light, double vision, blurred contours, photophobia).

From the urinary system: increased frequency of urination, polyuria.

From the reproductive system: pain in the lower abdomen, vaginal dryness.

From the endocrine system: hardening of the mammary glands, dysmenorrhea, pathological uterine bleeding, enlargement of the ovary (including cystic); rarely – pain in the mammary glands.

When treated with clomiphene, the likelihood of multiple pregnancy, ectopic pregnancy, endometriosis, and the growth of existing uterine fibroids increases.

Cystic enlargement of the ovaries is possible, especially with Stein-Leventhal syndrome. In these cases, the size of the ovaries can reach 4-8 cm. In this case, you should monitor the body temperature and stop treatment as soon as it becomes biphasic.

Dermatological reactions: rarely – alopecia.

From the side of metabolism: rarely – increase or decrease in body weight.

Allergic reactions: rarely – rash, urticaria, allergic dermatitis, vasomotor disorders.

Other: sensations of a rush of blood to the face with a feeling of heat (stop after finishing taking the drug).

Interaction

Compatible with gonadotropic hormone preparations.

Overdose

Symptoms: nausea, vomiting, vasomotor reactions, sensations of a rush of blood to the face, visual disturbances (decreased visual acuity, flashes, scotoma), enlarged ovaries and pain in the pelvic organs and abdomen.

Treatment: measures aimed at removing clomiphene from the body; carrying out maintenance therapy. There are no data on the possibility of elimination of clomiphene during dialysis.

Storage conditions

Store at 15-25°C.

Shelf life

5 years.

Manufacturer

EGIS, Hungary